Related by context. All words. (Click for frequent words.) 69 ENMD # 69 Sym# 67 OMP #M# 66 JAK inhibitor 66 PDE4 inhibitor 66 Mipomersen 66 kinase inhibitor 66 Phase Ib clinical 66 OXi# 66 Phase Ib study 66 ISIS # 66 PSN# [002] 66 CYC# 66 Carfilzomib 66 CCX# 66 cediranib 66 PXD# 66 Nanobody 66 Dapagliflozin 66 selective androgen receptor modulator 65 Tarvacin TM 65 Symadex 65 Phase 2a trial 65 ganetespib 65 obatoclax 65 PRT# 65 huC# DM4 65 angiogenesis inhibitor 65 Phase 1b 65 AP# [003] 65 HuMax EGFr 65 PEG SN# 65 deforolimus 65 phase IIa clinical 65 CR# vcMMAE 64 JAK1 64 orally bioavailable 64 small molecule activators 64 Guanilib 64 oral prodrug 64 Phase Ib 64 alvespimycin 64 enzastaurin 64 Blinatumomab 64 PEG Interferon lambda 64 R#/MEM # 64 CRLX# 64 Phase 1a clinical 64 vascular disrupting agent 64 Factor VIIa 64 investigational humanized monoclonal antibody 64 dacetuzumab 64 Panzem 64 targeting CD# 64 HuLuc# 63 novel peptide 63 atacicept 63 Nanobody ® 63 Dasatinib 63 CCR9 63 Tarvacin 63 Phase 1b trial 63 INCB# [001] 63 pomalidomide 63 phase IIb clinical 63 CCR9 antagonist 63 AEG# 63 preclinical 63 vascular disrupting agents 63 Atiprimod 63 Azedra 63 elotuzumab 63 CBLC# 63 CA4P 63 Phase Ib II 63 CG# [003] 63 Hsp# inhibition 63 trodusquemine 63 Curaxin 63 BAY #-# 63 DXL# 63 preclinically 63 CYT# 63 Traficet EN 62 imetelstat 62 ESBA# 62 cannabinor 62 Enzastaurin 62 LY# [003] 62 GRN# 62 HCV protease inhibitor 62 Phase 2a clinical 62 LY# [002] 62 vidofludimus 62 PSMA ADC 62 BiTE antibody 62 Tesetaxel 62 MGCD# [001] 62 Phase 2a 62 PNP inhibitor 62 HGS# 62 HQK 62 RGB # 62 TG# [003] 62 PRX # 62 phase IIb 62 orally dosed 62 NXL# 62 OncoVEX 62 elacytarabine 62 IMA# 62 immunotherapeutic agent 62 VA# [002] 62 HGS ETR1 62 epothilones 62 IAP inhibitors 62 JAK3 62 atrasentan 62 Hsp# inhibitors 62 MEK inhibitors 62 Squalamine 62 orally administered inhibitor 62 lintuzumab 62 BRIM2 62 OMP #R# 62 BRAF inhibitor 62 JAK2 inhibitor 62 Aplidin 62 TRV# [001] 62 HuMax CD# 62 delafloxacin 62 ApoB SNALP 61 tranilast 61 pan HDAC inhibitor 61 Sapacitabine 61 multi kinase inhibitor 61 Aurora kinase 61 depsipeptide 61 IRX 2 61 teduglutide 61 Triolex 61 GLYX 61 preclinical studies 61 TBC# 61 JAK inhibitors 61 investigational compound 61 Pimavanserin 61 teriflunomide 61 integrase inhibitor 61 L Annamycin 61 HDAC inhibitor 61 NP2 Enkephalin 61 INT# [002] 61 Ocrelizumab 61 Phase IIa trial 61 Plicera 61 forodesine 61 SPC# [001] 61 Pertuzumab 61 BCX# 61 Tyrima 61 PTH analogue 61 protein kinase inhibitor 61 XmAb# 61 Hsp# Inhibitor 61 TACI Ig 61 axitinib 61 metaglidasen 61 antiangiogenic activity 61 PROSTVAC TM 61 tezampanel 61 Alocrest 61 Phase #/#a 61 Tß4 61 receptor tyrosine kinase inhibitor 61 NGX# 61 OHR/AVR# 61 investigational monoclonal antibody 61 preclinical efficacy 61 talabostat 61 Trofex 61 PI3K/Akt pathway inhibitor 61 phase Ib 61 mTOR inhibitors 61 Bezielle 61 sapacitabine 61 selective kinase inhibitor 61 RLY# 61 Omacetaxine 61 HCV protease 61 IMC A# 61 antisense inhibition 61 cMET 61 CEQ# 61 seliciclib 61 GAP #B# 61 #ME# 61 antitumor 61 humanized anti 61 Kinase Inhibitor 61 phase IIa 61 riociguat 61 oxidative stress inducer 60 BAL# [001] 60 BioNumerik 60 ongoing Phase 1b 60 multicenter Phase II 60 investigational pan BCR 60 tyrosine kinase inhibitor 60 immunomodulator 60 Personalized Immunotherapy 60 ENMD 60 Atrasentan 60 Sphingomab 60 PI3K/mTOR 60 milatuzumab 60 GLP toxicology studies 60 MYDICAR ® 60 Novolimus 60 Aurora kinase inhibitor 60 KRN# 60 Phase IIb clinical trials 60 oral JAK1 60 Hedgehog signaling pathway 60 rNAPc2 60 placebo controlled Phase 60 MKC# MKC# PP 60 ATL# [001] 60 fosbretabulin 60 iSONEP 60 Angiolix 60 Phase 1b clinical 60 dose escalation Phase 60 proteasome inhibitors 60 humanized monoclonal antibody 60 GLPG# 60 therapeutic monoclonal antibody 60 pertuzumab 60 APOPTONE 60 immunomodulatory 60 HGS ETR2 60 OncoVEX GM CSF 60 Denufosol 60 Quinamed 60 Pralatrexate 60 Apixaban 60 liposomal formulation 60 elesclomol 60 Proxinium TM 60 anti leukemic 60 mertansine 60 TKM ApoB 60 proteasome inhibitor 60 CCR1 60 VEGF Trap 60 BZL# 60 Elesclomol 60 SAR# [004] 60 GMX# 60 MUC1 60 Hedgehog pathway 60 BCR ABL 60 Annamycin 60 ANG# 60 Romidepsin 60 dexpramipexole 60 epothilone 60 Bendavia 60 bortezomib Velcade 60 PI3K delta 60 Phase IIa clinical 60 oncolytic 60 ThGRF 60 CDK inhibitor 60 KB# [002] 60 TriRima 60 PI3 kinase 60 GRN#L 60 CCR2 60 Phase IIa 60 humanized antibody 60 MDV# 60 renin inhibitors 60 JAK2 inhibitors 60 Xanafide 60 Lixivaptan 60 oral antiviral 60 RAV# 60 eniluracil 60 Bortezomib 60 Vicinium TM 60 MEK inhibitor 60 trastuzumab DM1 T DM1 60 RDEA# 60 Hsp# inhibitor 60 rALLy clinical trial 60 allosteric modulation 60 otelixizumab 60 Olaparib 60 resolvins 60 allosteric modulator 60 Cloretazine R 60 IAP inhibitor 60 PDX pralatrexate 60 ToGA 60 visilizumab 60 Amrubicin 60 peripherally acting 60 Radezolid 59 SLx 59 PRECiSE 59 ALB # 59 torezolid phosphate 59 cathepsin K inhibitor 59 nucleotide analog 59 Archexin 59 antisense 59 sunitinib malate 59 phosphate S1P 59 R roscovitine 59 PCK# 59 PKC# 59 EP #R 59 novel anticancer 59 QLT# 59 TB4 59 TNFa 59 isatoribine 59 ImmunoVEX HSV2 59 CD# antibody [001] 59 T DM1 59 DU #b 59 phosphatidylserine PS targeting 59 histone deacetylase inhibitors 59 Thiarabine 59 immune modulating 59 EGFr 59 AVN# [001] 59 evaluating tivozanib 59 midstage clinical 59 MEK inhibitor RDEA# 59 antisense drug 59 Amigal 59 Phase 2b 59 DermaVir Patch 59 Phase 2b study 59 cancer immunotherapies 59 tubulin inhibitor 59 Gleevec resistant 59 volociximab 59 TPI ASM8 59 AQ4N 59 CYT# potent vascular disrupting 59 Ophena 59 docetaxel Taxotere R 59 HDAC Inhibitor 59 antisense inhibitors 59 HCD# [002] 59 antibody MAb 59 sodium glucose cotransporter 59 velafermin 59 selective agonist 59 Cloretazine 59 cilengitide 59 PI3K inhibitor 59 Fx #A 59 molecularly targeted 59 Imprime PGG 59 Vitaxin 59 adecatumumab 59 Perifosine 59 Elotuzumab 59 radezolid 59 TELINTRA 59 gamma secretase inhibitor 59 Randomized Phase 59 PLX# 59 VEGF inhibitors 59 Voreloxin 59 ATL/TV# 59 Kahalalide F 59 Trofex TM 59 BRIM3 59 radiation sensitizer 59 PARP inhibitor 59 fostamatinib 59 Talabostat 59 neratinib 59 siRNA therapeutics 59 Virulizin ® 59 Aliskiren 59 mGlu2 3 59 Darusentan 59 REP# 59 novel peptides 59 anticoagulant reversing agent 59 Phase III Pivotal 59 BiTE 59 Ozarelix 59 CoFactor 59 Muraglitazar 59 decitabine 59 HuMax CD4 59 histone deacetylase HDAC 59 targeted antifolate 59 randomized Phase III 59 Pazopanib 59 mitogen activated ERK kinase 59 NS4A 59 ELACYT 59 selective antagonist 59 GelSite R polymer 59 E2F Decoy 59 Litx 59 IMP# 59 selective inhibition 59 Targretin 59 ALN TTR# 59 PHX# 59 BMS# 59 HDAC inhibitors 59 Linaclotide 59 Onconase 59 FGFR 59 Cannabinor 59 BMS # 59 anti amnesic 59 peptibody 59 Prodarsan ® 59 p# inhibitor 59 sigma receptors 59 cangrelor 59 Alzhemed TM 59 oncolytic vaccine 59 Memryte 59 ALN VSP 59 laquinimod 59 OvaRex R 59 Panzem R 59 HDAC 59 SERMs 59 RNAi therapeutic targeting 59 LNPs 59 PS# [001] 59 Synavive 59 Genz # 59 incyclinide 59 AEZS 59 Vicriviroc 59 pharmacodynamic profile 59 PLK1 SNALP 59 LT NS# 59 Aflibercept 59 rBChE 59 SCH # 58 LEX System 58 protein tyrosine phosphatase 1B 58 Phase 2b trial 58 GRNVAC1 58 CTAP# Capsules 58 histone deacetylase HDAC inhibitor 58 Indaflex TM 58 targeted radiotherapeutic 58 DOS# 58 investigational drug 58 DiLA2 58 rFIXFc 58 IMC #B 58 AeroLEF TM 58 TRO# 58 phase IIb trial 58 Daclizumab 58 Seliciclib 58 Apoptone 58 PLX cells 58 acyclovir Lauriad R 58 anticancer agent 58 kinase inhibition 58 Epratuzumab 58 IDX# 58 Nuvion 58 anticancer compound 58 mTOR inhibition 58 chimeric monoclonal antibody 58 Tumor Necrosis Factor 58 DsiRNA 58 florbetaben 58 PDE4 inhibitors 58 small molecule inhibitor 58 CDK inhibitors 58 Valortim R 58 vivo efficacy 58 Panzem R NCD 58 AKT inhibitor 58 Capesaris 58 Phase 2b clinical 58 Oral NKTR 58 INCB# [003] 58 phase 2a 58 Akt inhibitor 58 investigational compounds 58 ZK EPO 58 IgG1 antibody 58 anticancer activity 58 TLR9 agonist 58 CCR5 antagonist 58 Alpharadin 58 A3 adenosine receptor 58 odanacatib 58 Rigel R# 58 Phase IIb trials 58 entinostat 58 small molecule agonists 58 Angiocept 58 ASONEP 58 MORAb 58 HSP# inhibitor 58 anti angiogenesis 58 PROCHYMAL 58 tanespimycin 58 small molecule tyrosine 58 IL# PE#QQR 58 signal transduction inhibitor 58 APEX PD 58 Cloretazine R VNP#M 58 thalidomide Thalomid 58 anti fibrotic 58 SRT# [003] 58 glufosfamide 58 ALN TTR 58 Pathway Inhibitor 58 Androxal TM 58 tiapamil 58 VEGF receptor 58 selective modulator 58 vinca alkaloid 58 polymerase inhibitors 58 ORAL Sync 58 YONDELIS 58 nucleoside 58 long acting muscarinic 58 MAb 58 Beta catenin 58 non nucleoside inhibitor 58 AMD# [003] 58 PI3 kinase inhibitors 58 ataluren 58 deacetylase inhibitors 58 Teriflunomide 58 hA# 58 Exherin TM 58 EndoTAG TM -1 58 FGFR1 58 romidepsin 58 Ofatumumab 58 pharmacological chaperone 58 chemokine receptor 58 Telaprevir 58 eltrombopag 58 Phase 2a clinical trials 58 Iloperidone 58 AEGR 58 seliciclib CYC# 58 Elagolix 58 cobiprostone 58 MEND CABG 58 LUX Lung 58 daclizumab 58 mGluR2 NAM 58 synthetic peptide 58 Ostabolin C 58 methylnaltrexone 58 glucagon receptor 58 Cloretazine ® 58 trial evaluating PRX# 58 nucleoside analog 58 Omnitarg 58 alagebrium 58 nicotinic alpha 7 58 PORxin TM 58 CXCR7 58 lumiliximab 58 preclinical pharmacokinetic 58 registrational trial 58 ANAVEX #-# [003] 58 small molecule inhibitors 58 pharmacodynamic PD 58 trastuzumab emtansine T DM1 58 bosutinib 58 peptide antigens 58 PsychoGenics 58 PI3K inhibitors 58 olaparib 58 Inhaled nitric oxide 58 factor receptor FGFR 58 GALNS 58 antitumor activity 58 solithromycin 58 LymphoStat B 58 varespladib 58 generation antisense 58 AVE# 58 anti angiogenic 58 Exelixis XL# 58 HDL Mimetic Peptide 58 aflibercept 58 ALN RSV# 58 antiproliferative effects 58 kinase inhibitors 58 tosedostat 58 DCCR 58 anti CD3 58 relapsed multiple myeloma 58 LCP AtorFen 58 ZD# [001] 58 Tarceva TM 58 follicular NHL 58 highly selective inhibitor 58 EOquin 58 CINOD 58 immunoregulatory 58 SERCA2a 58 Anticalin 58 ponatinib 58 Boceprevir 58 MAP# 58 Aeroquin 58 brivaracetam 58 immune modulation 58 ixabepilone 57 MYDICAR 57 XmAb 57 SGLT2 57 Enobia 57 anticancer agents 57 Ridaforolimus 57 tafamidis 57 glucokinase activator 57 Candesartan 57 alkylating agent 57 myelofibrosis polycythemia vera 57 selective androgen receptor modulators 57 CD3 monoclonal antibody 57 Tezampanel 57 pradefovir 57 ALK inhibitor 57 dose escalation trial 57 TLK# 57 flavopiridol 57 PARP inhibitors 57 ProLindac 57 Pivotal Trial 57 EZN 57 IMGN# 57 erythropoietic 57 Temsirolimus 57 potent anticancer 57 NVA# 57 CB2 selective receptor agonist 57 perifosine 57 Vidofludimus 57 VAPRISOL 57 pro angiogenic 57 retaspimycin 57 oral salmon calcitonin 57 Phase 2a Clinical Trial 57 BCR ABL inhibitors 57 SNT MC# 57 Dacogen injection 57 oral picoplatin 57 demonstrated antitumor activity 57 Targeted Chemotherapy 57 Systemic Delivery 57 ProSavin 57 ocrelizumab 57 biased ligand 57 velafermin belinostat 57 potent inhibition 57 antibody fragment 57 randomized Phase IIb 57 BN# [002] 57 TLR8 57 Eculizumab 57 Deforolimus 57 ENDEAVOR IV 57 potent topoisomerase II 57 RezularTM 57 DCVax R 57 Phase #b/#a 57 rilonacept 57 Excellarate 57 CRD5 57 P#X# 57 ARIKACE 57 xenograft models 57 TRAIL receptor antibodies 57 mTOR inhibitor 57 Azedra TM 57 sorafenib Nexavar 57 RSD# oral 57 PROMACTA 57 rxRNA 57 Phase 2b Clinical Trial 57 CD# CEA 57 GVAX ® 57 Cethromycin 57 ASA# 57 NPC 1C 57 GV# [001] 57 uricase 57 GAMMAGARD 57 next generation URAT1 57 Lu AA# 57 GGF2 57 vitro experiments 57 neuroprotective properties 57 Phase #b/#a trial 57 Lpathomab 57 HuCAL antibodies 57 Anticalin R 57 Phase IIa trials 57 Chemokine Therapeutics 57 generation proteasome inhibitor 57 LymphoStat B TM 57 Curaxins 57 HDACi 57 Zalypsis 57 ATL# [002] 57 intranasal formulation 57 Fc fusion protein 57 Eg5 57 tesmilifene 57 gastrin 57 Phase Ia 57 Crizotinib 57 CXB# 57 eculizumab 57 antisense drugs 57 FOLOTYN ® 57 ZYBRESTAT fosbretabulin 57 eprotirome 57 LBH# 57 antiviral therapeutics 57 Neuvenge 57 adipiplon 57 pazopanib 57 pivotal bioequivalence 57 S/GSK# 57 bardoxolone methyl 57 GATTEX TM 57 SinuNase ™ 57 CaPre TM 57 Phase #/#a trial 57 CD# monoclonal antibody 57 MOZOBIL 57 novel histone deacetylase 57 bicifadine 57 mGluR5 negative 57 NEUGENE 57 immune modulator 57 SMT C# 57 LSI #P 57 druggable targets 57 TÎ ² 4 57 Cloretazine VNP#M 57 AMPK activators 57 lorvotuzumab mertansine 57 Dalbavancin 57 adalimumab Humira 57 pharmacokinetic PK 57 IIa trial 57 CTLA 4 57 Affinitak 57 oligonucleotide therapeutics 57 arzoxifene 57 vicriviroc 57 carfilzomib 57 Trophos 57 lomitapide 57 bevacizumab Avastin ® 57 Spiegelmer ® 57 vWF 57 Degarelix 57 teplizumab 57 PTP 1B 57 PEGylated 57 Myocet 57 hypoxia inducible factor 57 PS# DARA 57 NIC5 57 tasocitinib 57 leukemia AML 57 taxane derivative 57 Presents Preclinical Data 57 ascending dose 57 MOR# 57 LEVADEX 57 dirucotide 57 ZFP Therapeutic 57 BHT DNA 57 DNA intercalator 57 Cetrorelix 57 indibulin 57 tolvaptan 57 administered subcutaneously 57 diagnostic biomarker 57 SPRYCEL ® 57 Myolimus 57 CIMZIA ™ 57 investigational therapies 57 selective estrogen receptor 57 corticosteroid dexamethasone 57 denufosol 57 delta isoform 57 LPA1 receptor 57 IND submission 57 PI3K 57 Tarvacin Anti Viral 57 TAKSTA 57 PrevOnco 57 #I TM# 57 Debio 57 leading oral taxane 57 Phase III clinical 57 Fibrillex TM 57 PRX# 57 BRAF inhibitors 57 paclitaxel Taxol 57 ZYBRESTAT 57 ADX# 57 MT# MEDI 57 multitargeted 57 #th Annual Interscience 57 SinuNase 57 tigecycline 57 Bavituximab 57 placebo controlled clinical 57 registrational 57 IL #E 57 XYOTAX TM 57 HDAC inhibition 57 MetMAb 57 polyclonal antibody 57 Hedgehog antagonist 57 ELND# 57 Abeta# 57 mipomersen 57 Chemophase 57 telomerase inhibitor 57 dasatinib 57 Tarmogen 57 ALN PCS 57 TRIOLEX 57 Posiphen 57 alpha7 57 Saforis 57 canagliflozin 56 investigational oral 56 ADVANCE PD 56 randomized controlled Phase 56 abiraterone 56 novel immunomodulatory 56 ABL inhibitor 56 castration resistant prostate cancer 56 IGF 1R 56 Laquinimod 56 Safinamide 56 RANK ligand 56 C5a 56 antiangiogenic 56 HER1 56 Catena ® 56 ON #.Na 56 serine protease 56 factor Xa inhibitor 56 zileuton 56 Pervasis 56 class mGluR5 inhibitor 56 favorable pharmacokinetic profile 56 IMiDs R 56 tkRNAi 56 anticancer therapeutics 56 Pivotal Study 56 Tanespimycin 56 trabectedin 56 enzyme inhibitors 56 maturation inhibitor 56 eosinophilic asthma 56 vorinostat 56 GDIR 56 Vandetanib 56 StemEx 56 tolerability 56 PNT# 56 Ophena TM 56 Mpex 56 Solazed TM 56 Cleviprex TM clevidipine 56 ILLUMINATE 56 VitiGam 56 GSK# [002] 56 omacetaxine 56 L BLP# 56 Valdoxan 56 drug conjugate 56 veltuzumab 56 Interferon alpha 56 cariprazine 56 gefitinib Iressa 56 MultiStem 56 MGCD# [002] 56 Phase 1b clinical trials 56 GPR# agonist 56 Chrysalin 56 galiximab 56 Tolvaptan 56 parathyroid hormone PTH 56 Preclinical Data 56 insulin sensitizing 56 Naproxcinod 56 Serdaxin 56 RNAi therapeutic 56 Phase Ib clinical trials 56 Phase IIb clinical 56 gamma secretase inhibitors 56 small molecule activator 56 XL# XL# 56 fidaxomicin Phase 3 56 Bucindolol 56 PROSTVAC VF 56 tipifarnib 56 Onco TCS 56 Nanobodies ® 56 Phase #b/#a clinical 56 EpCAM 56 Marqibo 56 imatinib Gleevec ® 56 nalbuphine ER 56 HCV replication 56 p# inhibitors 56 NeuroVax 56 EGFR inhibitors 56 AACR NCI EORTC 56 Lisofylline LSF 56 Liposomal 56 reslizumab 56 Ostarine 56 Vilazodone 56 oral renin inhibitor 56 synthetic retinoid 56 Hematide TM 56 systemic RNAi therapeutic 56 Ceflatonin R 56 OMNARIS HFA 56 FLT3 56 thrombopoietin 56 hedgehog pathway 56 Marqibo TM 56 Vernakalant 56 EOquin TM 56 cardioprotective effects 56 Cotara 56 Factor Xa 56 #beta HSD1 56 ocular formulation 56 CIMZIA TM 56 WT1 56 Elvitegravir 56 Eltrombopag 56 dacetuzumab SGN 56 apoptotic pathway 56 Methylnaltrexone 56 Phase 1a 56 telomerase inhibitor drug 56 Aurora kinase inhibitors 56 Ceflatonin 56 inhaled formulation 56 Phase III Clinical Trials 56 vivo validation 56 MKC# MT 56 Inhalation Solution 56 ostarine 56 XL# [003] 56 ALV# 56 TMC# [002] 56 anti angiogenic drugs 56 Relivar 56 farletuzumab 56 Tβ4 56 nanoviricides 56 FTY# fingolimod 56 nilotinib 56 stable nucleic acid 56 siRNA therapeutic 56 APD# 56 thrombin receptor 56 galectin 3 56 alpha antagonist 56 HIV integrase inhibitors